Norbert G. Riedel
At a glance: Norbert G. Riedel is Director at Jazz Pharmaceuticals (JAZZ). Their latest SEC Form 4, filed Mar 2, 2026, reported a sale of $656K. On file: 0 purchase lines ($0) and 1 sale line ($656K).
Disclosed holdings: about $1.7M of JAZZ stock: 7,024 shares reported on their latest Form 4 (filed Mar 2, 2026), valued at the Nov 19, 2026 close of $235.62. This counts only JAZZ shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Jazz Pharmaceuticals plc (JAZZ)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Norbert G. Riedel's InsiderPrint
3 trades from SEC Form 4 filings, 2020 to 2026, drawn as one fingerprint.
Reading this print: Mostly buys, trading about once a year, typically $223K a trade.
- Bump outward: a purchase (2)
- Dent inward: a sale (1)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- David W. KemperChair · CBSH · 100% match
- David J. ContisDirector · ELS · 100% match
- Robert ManzoDirector · VTOL · 99% match
- Jeffrey J. Jones IICEO, President · HRB · 99% match
- Richard KinzleyDirector · OKLO · 98% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Mar 2SEC | JAZZJazz Pharmaceuticals plc | Sell | 3,4157,024 held (−33%) | $192.00 | $656K | +22.7% |
- Sell
Director Norbert G Riedel sold $656K of JAZZ at $192.00 — cuts the stake by 33%.
Follow Norbert G. Riedel
Get one email when Norbert G. Riedel files a new purchase or sale. Free.
At most one email a day about Norbert G. Riedel, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.